Can I Take Omega-3 (EPA/DHA) with Provigil (Modafinil)?

What Is the Interaction Between Modafinil and Omega-3?

The combination of modafinil and omega-3 fatty acids carries no established pharmacokinetic drug-supplement interaction in the published literature. The concern that does exist is pharmacodynamic in nature, and it is dose-dependent. At daily EPA+DHA intakes below 3 g, the antiplatelet contribution of omega-3 is modest and unlikely to produce clinical bleeding risk on its own. Above 3 g/day, antiplatelet activity becomes measurable, and adding a stimulant-class medication that can mildly raise blood pressure could theoretically amplify cardiovascular monitoring needs.

Modafinil itself does not thin the blood, does not inhibit platelet aggregation, and does not alter lipid panels in any documented way. The two agents act through entirely different biological pathways.

Pharmacokinetic Profile of Modafinil

Modafinil is absorbed orally, reaches peak plasma concentration at roughly 2 to 4 hours, and has a half-life of 12 to 15 hours [1]. Hepatic metabolism occurs mainly through CYP3A4 and CYP3A5, with minor CYP2C19 involvement. It also weakly induces CYP3A4 and inhibits CYP2C19 at steady state, which is clinically relevant only for drugs whose clearance depends heavily on those enzymes.

Fish oil and EPA/DHA supplements do not meaningfully inhibit or induce CYP3A4 or CYP2C19 at any standard dietary or supplemental dose. A 2009 in-vitro study published in Drug Metabolism and Disposition examined omega-3 fatty acid effects on CYP enzyme kinetics and found no significant inhibition at physiologically relevant concentrations [2]. That finding has been replicated in subsequent human pharmacokinetic reviews.

Pharmacodynamic Profile of Omega-3 (EPA/DHA)

EPA and DHA exert their cardiovascular effects through at least three pathways: (1) reducing hepatic VLDL triglyceride synthesis, (2) inhibiting platelet aggregation via thromboxane A2 suppression, and (3) producing anti-inflammatory oxylipins called resolvins and protectins [3]. The antiplatelet mechanism is the only one that overlaps in any meaningful way with modafinil's cardiovascular profile, and only when omega-3 doses exceed typical dietary amounts.

The REDUCE-IT trial (N=8,179) demonstrated that icosapentaenoic acid (EPA) at 4 g/day reduced major adverse cardiovascular events by 25% compared to placebo over a median 4.9 years, but also noted a small increase in atrial fibrillation and peripheral edema in the treatment group [4]. Bleeding was not significantly elevated in REDUCE-IT, which provides relevant safety context for high-dose EPA monotherapy.

How Modafinil Is Metabolized and Why It Matters for Supplements

Understanding modafinil's metabolism is the foundation for assessing any supplement interaction. The drug is processed mainly in the liver, and anything that meaningfully disrupts CYP3A4 activity could alter its plasma exposure.

CYP3A4 and CYP2C19 Relevance

Modafinil's plasma exposure can rise if a strong CYP3A4 inhibitor is co-administered, or fall with a strong inducer. Omega-3 fatty acids are neither. The Natural Medicines database (Therapeutic Research Center) rates the omega-3 and modafinil combination as having insufficient evidence for a clinically meaningful interaction, and does not flag a CYP-based pharmacokinetic concern [5].

CYP2C19 inhibition by modafinil is clinically relevant for drugs like omeprazole, diazepam, and phenytoin. EPA and DHA do not rely on CYP2C19 for their metabolism, so this pathway is not a concern for the combination.

Protein Binding Considerations

Modafinil is approximately 60% protein-bound, primarily to albumin. EPA and DHA also bind to albumin during transport. Protein-displacement interactions are rarely clinically significant unless both agents have narrow therapeutic windows and are highly protein-bound. Neither modafinil nor omega-3 fish oil meets that criterion.

Absorption Timing

Modafinil absorption is not meaningfully affected by food. Taking fish oil capsules with modafinil in the same meal does not alter modafinil peak concentration or half-life based on current pharmacokinetic data. No dose-separation window is required.

The Antiplatelet Question: When Does It Matter?

This is the section most clinicians focus on. Omega-3 fatty acids, particularly EPA, inhibit platelet aggregation by competing with arachidonic acid for cyclooxygenase enzymes and by reducing thromboxane A2 production. At doses of 1 to 2 g EPA+DHA per day (a standard fish-oil capsule contains roughly 300 to 600 mg combined EPA+DHA), the antiplatelet effect is mild and comparable to the dietary omega-3 intake in populations with high fish consumption.

Dose Thresholds for Antiplatelet Activity

A 2020 review published in Nutrients examined platelet function across omega-3 dose ranges and concluded that antiplatelet effects become consistently measurable only at doses above 3 g EPA+DHA daily, with more pronounced effects above 4 g/day [6]. Below 3 g/day, the effect on bleeding time in healthy adults without concurrent antiplatelet therapy was not clinically meaningful.

Modafinil does not contribute to antiplatelet activity. A search of the FDA Adverse Event Reporting System (FAERS) and published literature reveals no documented cases of clinically significant bleeding attributed to the modafinil plus omega-3 combination in isolation.

When the Combination Requires More Caution

The antiplatelet concern escalates when a third agent is added to the mix. Patients taking warfarin, rivaroxaban, apixaban, clopidogrel, aspirin (even low-dose 81 mg), or NSAIDs on a daily basis should discuss high-dose omega-3 use with their prescriber regardless of whether they are also on modafinil. The FDA's 2019 approval of icosapentaenoic acid (Vascepa) at 4 g/day included labeling language noting that patients on anticoagulants or antiplatelets should be monitored for bleeding [7].

Modafinil mildly raises blood pressure and heart rate in some users, particularly at the 400 mg daily dose. If a patient already has cardiovascular risk factors and is combining high-dose omega-3 with modafinil plus an antiplatelet, a cardiology or primary care review is reasonable before escalating omega-3 doses.

Cognitive Effects: Does Omega-3 Add to or Interfere with Modafinil's Wakefulness Action?

Modafinil promotes wakefulness primarily by blocking dopamine reuptake and, to a lesser extent, by activating orexin/hypocretin neurons [1]. EPA and DHA support neuronal membrane fluidity, reduce neuroinflammation, and may modestly support dopaminergic and serotonergic signaling over time. These mechanisms do not conflict.

Evidence for Cognitive Combination

A 2022 randomized controlled trial in Nutrients (N=176 healthy adults) found that 1.25 g/day of EPA+DHA for 26 weeks improved attention and processing speed scores compared to placebo [8]. That effect is smaller and slower-onset than modafinil's acute wakefulness action, but the two act through complementary rather than competing pathways.

No published trial has co-administered omega-3 and modafinil to directly measure combined cognitive outcomes. What exists is mechanistic plausibility and the absence of antagonism in the literature.

Neuroinflammation and Modafinil Tolerance

Some clinicians who prescribe modafinil off-label for cognitive support note that chronic neuroinflammation may blunt wakefulness-agent efficacy over time. EPA and DHA's anti-inflammatory effects, mediated partly through resolvin E1 and protectin D1 pathways documented in NCBI-indexed basic science literature [3], could theoretically maintain a more favorable neural environment. This is mechanistic reasoning rather than established clinical evidence, and prescribers should not substitute this logic for evidence-based decision-making.

Triglycerides, Cardiovascular Risk, and Modafinil

Omega-3 fatty acids at prescription doses lower fasting triglycerides by 20 to 45% depending on baseline levels and preparation used [4]. Modafinil has not been shown to alter fasting lipid panels in clinical trials.

Does Modafinil Affect Lipid Metabolism?

A review of modafinil's pharmacology in the context of its original clinical trials for narcolepsy (including the 12-week key trials submitted to the FDA) found no statistically significant change in total cholesterol, LDL, HDL, or triglycerides at doses of 200 to 400 mg/day [1]. Patients who start omega-3 therapy for triglyceride reduction do not need to adjust modafinil dosing on that basis.

Cardiovascular Monitoring Considerations

Modafinil labeling includes a warning for serious skin reactions and cardiovascular events in patients with known cardiac arrhythmias. The FDA prescribing information for Provigil states: "Modafinil has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable angina, and such patients should be treated with caution" [7].

Patients fitting that description who are also initiating high-dose omega-3 therapy should have baseline and follow-up cardiovascular assessments regardless of the supplement-drug combination.

Practical Guidance: Taking Omega-3 and Modafinil Together

Most adults taking modafinil for narcolepsy, shift-work sleep disorder, or obstructive sleep apnea can safely consume standard fish-oil supplements (providing up to 2 g EPA+DHA daily) without adjusting their modafinil regimen. Standard dietary fish consumption adds another 0.2 to 0.5 g EPA+DHA per day for most Americans, well below any threshold of concern.

Recommended Approach by Patient Profile

Healthy adults without anticoagulant therapy. Standard omega-3 supplementation (1 to 2 g EPA+DHA/day) alongside modafinil 100 to 400 mg/day requires no special precautions or timing adjustments. Routine follow-up at scheduled medication reviews is sufficient.

Adults on warfarin or direct oral anticoagulants. Before adding omega-3 at any dose above 1 g/day, confirm with your prescriber. INR monitoring may need to be more frequent during the first 4 to 6 weeks after initiating or changing omega-3 dose. This precaution applies independently of modafinil.

Adults on aspirin or NSAIDs. At omega-3 doses below 3 g/day, the additive antiplatelet contribution is low. Above 3 g/day, discuss with your prescriber. Watch for unexplained bruising, prolonged bleeding from minor cuts, or blood in urine or stool.

Patients with narcolepsy or idiopathic hypersomnia on high-dose modafinil (400 mg/day). No specific omega-3 restriction applies on the basis of modafinil dose alone. The same antiplatelet dose thresholds apply.

What to Tell Your Prescriber

At your next appointment, mention:

• The brand or formulation of omega-3 you use (concentrated EPA-only products like Vascepa differ meaningfully from standard fish oil)
• The daily dose in milligrams of EPA and DHA combined
• Any other supplements with antiplatelet properties (vitamin E above 400 IU, garlic extract, ginkgo biloba, nattokinase)
• Any cardiovascular symptoms that have changed since starting either agent

The American Heart Association recommends that patients with documented coronary heart disease consume approximately 1 g/day of EPA+DHA, and that those with elevated triglycerides consider 2 to 4 g/day under physician supervision [9].

Summary of the Interaction Classification

No pharmacokinetic interaction between omega-3 fatty acids and modafinil has been established. The pharmacodynamic concern is antiplatelet potentiation at omega-3 doses above 3 g EPA+DHA per day, and that concern is most relevant when a third antiplatelet or anticoagulant agent is present in the regimen. For the majority of modafinil users taking a standard fish-oil supplement, the combination is considered safe based on current evidence. Patients should disclose all supplements to their prescribing clinician, and those on anticoagulants should confirm omega-3 dosing before escalating beyond 1 g/day.

If you are taking more than 3 g EPA+DHA per day alongside any antiplatelet or anticoagulant medication, ask your prescriber to review the full regimen at your next visit.